Literature DB >> 17150365

Lead discovery and optimization of T-type calcium channel blockers.

Jung Hwan Park1, Jin Kyu Choi, Eunjung Lee, Jae Kyun Lee, Hyewhon Rhim, Seon Hee Seo, Yoonjee Kim, Munikumar Reddy Doddareddy, Ae Nim Pae, Jahyo Kang, Eun Joo Roh.   

Abstract

A series of compounds were designed as T-type calcium channel blocker containing 6 or 5 pharmacophore features from structure-based virtual screening. To optimize the suggested structure, over 130 derivatives were synthesized and their inhibitory activities on T-type calcium channel were assayed using in vitro screening system with alpha1(G) and alpha1(H) clones. For the compounds with higher activities in FDSS assay system, the efficacy was measured by patch-clamp method. Among the library with 5 features, alkaneamide derivatives (7b, 9j, 11b, 11g, 11h) with 4-arylsubstituted piperazine showed better IC(50) values than Mibefradil.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17150365     DOI: 10.1016/j.bmc.2006.11.004

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  3 in total

1.  Investigation of various N-heterocyclic substituted piperazine versions of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol: effect on affinity and selectivity for dopamine D3 receptor.

Authors:  Dennis A Brown; Manoj Mishra; Suhong Zhang; Swati Biswas; Ingrid Parrington; Tamara Antonio; Maarten E A Reith; Aloke K Dutta
Journal:  Bioorg Med Chem       Date:  2009-04-19       Impact factor: 3.641

Review 2.  T-type calcium channel blockers as neuroprotective agents.

Authors:  Benjamin J Kopecky; Ruqiang Liang; Jianxin Bao
Journal:  Pflugers Arch       Date:  2014-02-25       Impact factor: 3.657

3.  Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkinson's disease.

Authors:  Balaram Ghosh; Tamara Antonio; Maarten E A Reith; Aloke K Dutta
Journal:  J Med Chem       Date:  2010-03-11       Impact factor: 7.446

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.